From: Role of serum S100B and PET-CT in follow-up of patients with cutaneous melanoma
Pts with stage I or II (68) | ||||
---|---|---|---|---|
 | PPV % (N) | NPV% (N) | Sensitivity% (N) | Specificity% (N) |
S100B | 80.0% (28/35) | 21.2% (7/33) | 51.8% (28/54) | 50.0% (7/14) |
PET-CT | 98.2% (54/55) | 100.0% (13/13) | 100.0% (54/54) | 92.8% (13/14) |
With clin. sign (48) | ||||
 | PPV% (N) | NPV% (N) | Sensitivity% (N) | Specificity% (N) |
S100B | 93.3 (14/15) | 21.3 (7/33) | 65.0 (26/40) | 87.5 (7/8) |
PET-CT | 97.5 (40/41) | 100.0 (7/7) | 100.0 (40/40) | 87.5 (7/8) |
Asymptomatic pts (20) | ||||
 | PPV% (N) | NPV% (N) | Sensitivity% (N) | Specificity% (N) |
S100B | 70.0 (14/20) | 0 bias | 100.0 (14/14) | 0 bias |
PET-CT | 100.0 (14/14) | 100.0 (6/6) | 100.0 (14/14) | 100.0 (6/6) |